Elevated baseline hsCRP is associated with a higher burden of physical symptoms at end of treatment in SSRD patients.
•Baseline IL-6 was not associated with depression, anxiety, physical or pain symptoms at end of treatment in SSRD patients.
•hsCRP may be a useful factor in identifying SSRD patients who are at risk of a persistent high physical symptom burden.
AbstractObjectiveTo investigate the roles of hsCRP and IL-6 as prognostic markers for treatment outcome in SSRD.
MethodsIn this prospective cohort study, 237 consecutive outpatients diagnosed with SSRD at the Clinical Centre of Excellence for Body Mind and Health, the Netherlands were assessed. At intake, venepuncture was performed for serum hsCRP and IL-6. Baseline scores for PHQ-9, GAD7, physical symptom score (PSQ-51) and BPI questionnaires were obtained. Patients were followed up at the end of their usual treatment programme, which lasted approximately 12 months.
ResultsHigher baseline hsCRP was associated with high physical symptom scores (PSQ-51), but not BPI, GAD-7 and PHQ-9 questionnaire scores at end of treatment. No association was identified between baseline IL-6 and follow-up symptom questionnaire scores after treatment. Adjustment for age, gender and somatic comorbidity showed no significant change in the association.
ConclusionThis exploratory analysis provides some evidence that in patients with SSRD, high baseline serum hsCRP may predict poorer treatment outcomes in physical symptoms but not depression, anxiety or pain symptoms. Baseline serum hsCRP may therefore be a useful factor in identifying SSRD patients who are at risk of a persistent high physical symptom burden.
KeywordsSomatic symptom disorder and related disorders
Conversion disorder
Functional neurological disorder
hsCRP
Systemic low-grade inflammation
IL-6
© 2022 The Author(s). Published by Elsevier Ltd.
留言 (0)